Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Authors
Keywords
-
Journal
BLOOD
Volume 124, Issue 26, Pages 3870-3879
Publisher
American Society of Hematology
Online
2014-10-31
DOI
10.1182/blood-2014-03-563627
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002
- (2014) David A. Rizzieri et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group
- (2013) T. Wasterlid et al. ANNALS OF ONCOLOGY
- Suboptimal dosing of rituximab in male and female patients with DLBCL
- (2013) M. Pfreundschuh et al. BLOOD
- Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
- (2013) L. J. Costa et al. BLOOD
- Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database
- (2013) Jorge J. Castillo et al. CANCER
- High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program
- (2013) T. Intermesoli et al. HAEMATOLOGICA
- Low-Intensity Therapy in Adults with Burkitt's Lymphoma
- (2013) Kieron Dunleavy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
- (2012) C. Muller et al. BLOOD
- Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia
- (2012) Yvette L. Kasamon et al. LEUKEMIA & LYMPHOMA
- Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis
- (2011) J. A. Barnes et al. ANNALS OF ONCOLOGY
- RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma
- (2011) Gaetano Corazzelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial
- (2011) Torben S. Mikkelsen et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
- (2011) Sara Raponi et al. LEUKEMIA & LYMPHOMA
- Intrathecal Vincristine
- (2009) Bernadette Hennipman et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
- (2008) G. M. Mead et al. BLOOD
- High‐dose chemotherapy and immunotherapy in adult Burkitt lymphoma
- (2008) Albert Oriol et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More